In the most recent analysis, the median progression-free survival was 29.7 months in the lanreotide-everolimus arm and 13.6 months in the everolimus-alone arm. The combination of lanreotide and ...

Findings from a recently presented study demonstrated that patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may benefit from treatment with Afinitor ...

Michael McWhertor is a journalist with more than 17 years of experience covering video games, technology, movies, TV, and entertainment. So it stands to reason the animated intro may also provide ...